415 related articles for article (PubMed ID: 24819152)
1. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
3. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
4. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide-induced apoptosis of Hep-2 cell line through modulating intracellular glutathione (GSH) level.
Cheng B; Yang X; An L; Gao B; Liu X
Auris Nasus Larynx; 2010 Feb; 37(1):89-94. PubMed ID: 19574005
[TBL] [Abstract][Full Text] [Related]
6. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
[TBL] [Abstract][Full Text] [Related]
7. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells.
Li H; Wang Y; Xu W; Dong L; Guo Y; Bi K; Zhu C
Acta Haematol; 2015; 133(1):18-25. PubMed ID: 24993472
[TBL] [Abstract][Full Text] [Related]
9. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Sahu GR; Jena RK
Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
[TBL] [Abstract][Full Text] [Related]
10. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
[TBL] [Abstract][Full Text] [Related]
11. Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid.
Dilda PJ; Perrone GG; Philp A; Lock RB; Dawes IW; Hogg PJ
Int J Biochem Cell Biol; 2008; 40(5):1016-29. PubMed ID: 18160327
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
13. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
14. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
16. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
[TBL] [Abstract][Full Text] [Related]
18. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
19. Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
Maimaitiyiming Y; Wang C; Xu S; Islam K; Chen YJ; Yang C; Wang QQ; Naranmandura H
Metallomics; 2018 Jun; 10(6):828-837. PubMed ID: 29774349
[TBL] [Abstract][Full Text] [Related]
20. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
